11 research outputs found
PDB40 The Importance of HbA1C Evolution in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus (T2DM)
Get PDFEstimating the Lifetime Health Outcomes of Type 2 Diabetes Mellitus (T2dm) Patients Inadequately Controlled on Metformin Plus Sulphonylurea Receiving Either Canagliflozin or Sitagliptin Using the UKPDS Outcomes Model V1.3
No full textPSY182 - A TARGETED REVIEW OF HAEMATOLOGY SINGLE TECHNOLOGY APPRAISALS (STAS) BY NICE SINCE THE INTRODUCTION OF THE NEW CANCER DRUGS FUND (CDF)
No full textPDB41 The Cost-Effectiveness of Getting to Glucose, Blood Pressure, and Lipid Goals in Patients Newly Diagnosed with Type 2 Diabetes Mellitus (T2DM) and Younger Than Fifty in Sweden
No full textPDB43 The Economic Impact of Weight Loss in Patients Newly Diagnosed with Type 2 Diabetes Mellitus (T2DM) and Younger Than Fifty in Sweden
No full textHealth Related Quality of Life Outcomes (Hrqol) and Resource Use Associated With Type 2 Diabetes Patients Taking Steps To Lose Weight In 5 European Countries
No full textThe Efficacy and Effectiveness in HBA1C-Lowering is Dependent on Baseline Body Mass Index (BMI) for Sitagliptin but not Canagliflozin in the Treatment of Type 2 Diabetes Mellitus (T2DM)
No full textPDB40 The Importance of HbA1C Evolution in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus (T2DM)
No full text
Is Canagliflozin Cost-Effective Compared to Sitagliptin Across Multiple Lines of Type 2 Diabetes Mellitus (T2dm) Therapy In Ireland?
No full text
